These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2692428)

  • 21. Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins.
    Knapp B; Hundt E; Enders B; Küpper HA
    Infect Immun; 1992 Jun; 60(6):2397-401. PubMed ID: 1587607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Can malaria be eradicated by vaccination?].
    Stürchler D
    Schweiz Rundsch Med Prax; 1987 Sep; 76(36):975-80. PubMed ID: 3310179
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasmodium falciparum: administration of anti-sporozoite antibodies during sporogony results in production of sporozoites which are not neutralized by human anti-circumsporozoite protein vaccine sera.
    do Rosario VE; Appiah A; Vaughan JA; Hollingdale MR
    Trans R Soc Trop Med Hyg; 1989; 83(3):305-7. PubMed ID: 2694460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The conformational restriction of synthetic peptides, including a malaria peptide, for use as immunogens.
    Satterthwait AC; Arrhenius T; Hagopian RA; Zavala F; Nussenzweig V; Lerner RA
    Philos Trans R Soc Lond B Biol Sci; 1989 Jun; 323(1217):565-72. PubMed ID: 2569211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.
    Patarroyo ME; Amador R; Clavijo P; Moreno A; Guzman F; Romero P; Tascon R; Franco A; Murillo LA; Ponton G
    Nature; 1988 Mar; 332(6160):158-61. PubMed ID: 2450281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA.
    Favuzza P; Blaser S; Dreyer AM; Riccio G; Tamborrini M; Thoma R; Matile H; Pluschke G
    Malar J; 2016 Mar; 15():161. PubMed ID: 26979066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malaria vaccines. Are they approaching reality?
    Perlmann P
    Nature; 1987 Jul 16-22; 328(6127):205-6. PubMed ID: 3299105
    [No Abstract]   [Full Text] [Related]  

  • 28. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.
    Kublin JG; Lowitt MH; Hamilton RG; Oliveira GA; Nardin EH; Nussenzweig RS; Schmeckpeper BJ; Diggs CL; Bodison SA; Edelman R
    Vaccine; 2002 Mar; 20(13-14):1853-61. PubMed ID: 11906775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of protective immunity against experimental infection with malaria using synthetic peptides.
    Patarroyo ME; Romero P; Torres ML; Clavijo P; Moreno A; Martínez A; Rodríguez R; Guzman F; Cabezas E
    Nature; 1987 Aug 13-19; 328(6131):629-32. PubMed ID: 3302727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of protective immunity to malaria.
    Anders RF; Brown GV; Coppel RL; Kemp DJ
    Lepr Rev; 1986 Dec; 57 Suppl 2():245-53. PubMed ID: 3553798
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
    Herrington DA; Clyde DF; Losonsky G; Cortesia M; Murphy JR; Davis J; Baqar S; Felix AM; Heimer EP; Gillessen D
    Nature; 1987 Jul 16-22; 328(6127):257-9. PubMed ID: 2439920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malaria vaccine development using synthetic peptides as a technical platform.
    Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
    Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current state of the studies of malaria vaccine].
    Dzbeński TH
    Przegl Epidemiol; 1990; 44(3):173-8. PubMed ID: 2084799
    [No Abstract]   [Full Text] [Related]  

  • 34. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.
    Xu H; Hodder AN; Yan H; Crewther PE; Anders RF; Good MF
    J Immunol; 2000 Jul; 165(1):389-96. PubMed ID: 10861076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a sporozoite malaria vaccine.
    Nussenzweig V; Nussenzweig RS
    Am J Trop Med Hyg; 1986 Jul; 35(4):678-88. PubMed ID: 2425647
    [No Abstract]   [Full Text] [Related]  

  • 36. Towards a malaria vaccine: what is in sight?
    del Giudice G
    Allergol Immunopathol (Madr); 1991; 19(3):129-35. PubMed ID: 1799171
    [No Abstract]   [Full Text] [Related]  

  • 37. Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.
    Triller G; Scally SW; Costa G; Pissarev M; Kreschel C; Bosch A; Marois E; Sack BK; Murugan R; Salman AM; Janse CJ; Khan SM; Kappe SHI; Adegnika AA; Mordmüller B; Levashina EA; Julien JP; Wardemann H
    Immunity; 2017 Dec; 47(6):1197-1209.e10. PubMed ID: 29195810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malaria vaccine against sporozoites?
    Nussenzweig V; Nussenzweig RS
    Ann Inst Pasteur Immunol (1985); 1985; 136D(3):301-12. PubMed ID: 3913382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression systems that best mimic native structure: which ones to try first and why.
    Chang SP
    Am J Trop Med Hyg; 1994; 50(4 Suppl):11-9. PubMed ID: 7513505
    [No Abstract]   [Full Text] [Related]  

  • 40. Lack of Ir gene control in the immune response to malaria. I. A thymus-independent antibody response to the repetitive surface protein of sporozoites.
    Schofield L; Uadia P
    J Immunol; 1990 Apr; 144(7):2781-8. PubMed ID: 2138652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.